ICON and IBM to Revolutionise Clinical Trial Feasibility, Patient Recruitment and Study Start-up Timelines
10 Setembro 2015 - 9:01AM
Business Wire
ICON applies IBM Watson Clinical Trial
Matching to Oncology Clinical Trials
ICON plc, (NASDAQ:ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it is working with IBM (NYSE:IBM) to help reduce the time and costs
of drug development, while also offering patients enhanced quality
of care by connecting them to relevant clinical trials. ICON will
tap Watson's cognitive computing power to help automate the
cumbersome process of identifying patients who meet the criteria
for a clinical trial, and to analyse protocols to assess trial
feasibility and identify optimal trial sites.
Initially, ICON is applying Watson Clinical Trial Matching to
its breast, lung, colon and rectal cancer trials. The solution
enables ICON to advise sponsors how many patients match their trial
criteria, where they are located and how they will recruit them.
IBM’s Watson Health Cloud will facilitate access to de-identified
patient data, including 50 million patient records contained in the
data set from Explorys, which IBM acquired in April. At the same
time, ICON enhances IBM Watson’s capabilities by providing
expertise into clinical trial protocols and clinical
operations.
The cost and time involved in clinical trials is considerable.
More than $1.3B is spent on patient recruitment by drug developers
each year and yet fewer than 5% of cancer patients participate in a
clinical trial. It also typically takes 6-12 months to start up a
global phase III drug trial and another 12 months to enroll the
required number of patients.
Commenting on the announcement, ICON’s Chief Operating Officer,
Dr. Steve Cutler, said: “Recruiting the required number of patients
for clinical trials is a constant challenge for our customers and
can represent more than 30% of total study costs. By applying IBM
Watson to our clinical trials, we have the potential to
revolutionise clinical trial feasibility, patient recruitment and
study start-up timelines which will help our customers take
significant time and cost from their development programmes.
Together with IBM, we are also providing a better and faster way to
connect patients with clinical trials that are most relevant to
them. Today’s announcement is an excellent example of disruptive
innovation and represents ICON and IBM’s shared vision for using
industry-leading technologies and real-word data sets to improve
clinical development.”
“Clinical trials are crucial in the drug and treatment
development process, but when it comes to identifying appropriate
trial candidates, there are significant data challenges, which can
contribute to delays for bringing new therapies to market,” said
Sean Hogan, Vice President and General Manager, IBM Healthcare.
“Through cognitive computing and cloud-based data, our goal is to
help our clients accelerate the time it takes to complete clinical
trials and reach conclusive trial results.”
About IBM Watson: Pioneering a New Era of Computing
Watson is the first commercially available cognitive computing
capability representing a new era in computing. The system,
delivered through the cloud, analyzes high volumes of data,
understands complex questions posed in natural language, and
proposes evidence-based answers. Watson continuously learns,
gaining in value and knowledge over time, from previous
interactions. In April 2015, the company launched IBM Watson Health
and the Watson Health Cloud platform. The new unit will help
improve the ability of doctors, researchers and insurers to
innovate by surfacing new insights from the massive amount of
personal health data being created daily. The Watson Health Cloud
allows this information to be de-identified, shared and combined
with a dynamic and constantly growing aggregated view of clinical,
research and social health data.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 81 locations in 37 countries and has approximately
11,300 employees.
Further information is available at
www.iconplc.com/innovation
Follow ICON on Twitter, LinkedIn and Facebook to receive the
latest company updates.
Learn more about this story at
http://asmarterplanet.com/blog/2015/09/using-data-analytics-speed-clinical-drug-trials.html
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150910005111/en/
ICONMedia ContactRebecca PowerWeber ShandwickTel:
+44 (0) 207 067 0866Email:
RPower@webershandwick.comorIBMMedia ContactLorie
FiberTel: + 1-646-318-0575
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024